Edgewise Therapeutics (EWTX) Research & Development (2020 - 2026)

Edgewise Therapeutics has disclosed Research & Development across 7 years of filings, most recently posting $42.7 million for Q1 2026.

• Research & Development for Q1 2026 came in at $42.7 million, up 16.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $157.3 million (up 15.62% YoY), and the FY2025 annual result was $151.4 million, up 19.24% from the prior year.
• Research & Development came in at $42.7 million for Q1 2026 at Edgewise Therapeutics, down from $43.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $43.6 million in Q4 2025 to a low of $11.1 million in Q1 2022.
• The 5-year median for Research & Development is $27.7 million (2024), against an average of $27.4 million.
• Across the five-year window, Research & Development surged 107.54% in 2022 and climbed 9.38% in 2025, its largest moves.
• Edgewise Therapeutics' Research & Development stood at $16.6 million in 2022, then surged by 66.65% to $27.7 million in 2023, then surged by 31.38% to $36.4 million in 2024, then gained by 19.86% to $43.6 million in 2025, then declined by 2.16% to $42.7 million in 2026.
• The last three Research & Development figures came in at $42.7 million (Q1 2026), $43.6 million (Q4 2025), and $37.5 million (Q3 2025), per Business Quant data.